Instem Acquires PDS Life Sciences to Help Clients Bring Life Enhancing Products to Market Faster and More Efficiently
Summary
This further consolidation by Instem of key application areas will help customers streamline and accelerate their research and development processes, while enabling clients to access data from across the R&D continuum, increasing the power of current and future in silico modelling and prediction solutions. Headquartered in Switzerland, with offices in the United States and Japan, PDS has been a direct competitor of Instem, providing software and outsourced services for non-clinical study management and regulatory submissions using SEND (the Standard for the Exchange of Non-clinical Data). By combining our technologies and talents we will be able to more quickly develop and deliver solutions that provide even higher value to our clients.” “This was a natural next step in our quest to help clients do more and go further than ever before,” states Vicente Nogués, CEO at PDS. We enable organizations in the life sciences to more efficiently collect, report and submit high quality regulatory data, while offering them the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information. Every day, across the entire drug development value chain, Instem solutions are meeting the rapidly expanding needs of life science organizations for data-driven decision making, leading to safer, more effective products.